Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT1 for prevention of pyrotinib-associated diarrhea in HER2-positive breast cancer
CTR20260926Phase 2Active
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of notoginsenoside Ft1 in diarrhea, sponsored by Chongqing Paijin Biotechnology. Started Apr 2026; status: active.
02
Drugs
notoginsenoside Ft1
03
Conditions
diarrhea
Beyond the preview
Go deeper on CTR20260926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260926.